Dr. Caroline Robert Discusses the MEK Inhibitor Trametinib METRIC Trial Results

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant MelanomaПодробнее

OS Results of a Study Evaluating Dabrafenib and Trametinib in MelanomaПодробнее

Webinar: Everything you need to know about the TiNT MEK Inhibitor Clinical TrialПодробнее

Data in Melanoma: Observing Trials and Unmet NeedsПодробнее

Considering Chemotherapy’s Value in MelanomaПодробнее

GSK2118436 (dabrafenib) with and without the oral MEK1/2 inhibitor GSK1120212 (trametinib)Подробнее

Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain MetastasesПодробнее

Caroline Robert: METRIC Phase 3 StudyПодробнее

The METRIC trial of trametinib, five years onПодробнее

COMBI-AD: Dabrafenib plus trametinib in advanced melanomaПодробнее

Dr. Adjei on Adverse Events From MEK InhibitorsПодробнее

Dabrafenib plus trametinib preferable to vemurafenib alone in melanomaПодробнее

Identifying and addressing treatment obstaclesПодробнее

Dr. Michael Rotkowitz on the Dabrafenib Plus Trametinib Combination for MelanomaПодробнее

Dr. Robert on Next Steps Following the Phase III COMBI-v Study in MelanomaПодробнее

Improved response rate and survival with dabrafenib plus trametinib vs vemurafenib alone in melanomaПодробнее

Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant MelanomaПодробнее

ESMO 2014: MelanomaПодробнее

Risk Stratification for Advanced MelanomaПодробнее